Stockscreener 앱 받기
11.42
0.71%
0.08
시간 외 거래:
11.26
-0.16
-1.40%
Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스
Ex-Genentech scientist joins Ira Mellman at Medici; Intellia poaches CMO from Scholar Rock - Endpoints News
Intellia Therapeutics names Jing Marantz as EVP and CMO - The Pharma Letter
Intellia Therapeutics names Jing Marantz as chief medical officer - Investing.com
Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer - Intellia Therapeutics
Price to earnings forward of Intellia Therapeutics, Inc. – BX:38I - TradingView
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock? - Zacks Investment Research
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock? - Yahoo Finance
To cover taxes, an Intellia Therapeutics (NTLA) officer sells 1,864 shares in a mandatory sale. - Stock Titan
Barclays Initiates Intellia Therapeutics at Underweight With $8 Price Target - marketscreener.com
Officer Eliana Clark proposes selling 57,750 Intellia Therapeutics (Nasdaq: NTLA) shares. - Stock Titan
Intellia Therapeutics Q2 2026 Earnings Call Transcript - Benzinga
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Eight new employees got Intellia stock awards, with vesting scheduled over three years. - Stock Titan
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Intellia Therapeutics (NTLA), What Is Drawing Fresh Attention Now? - Simply Wall Street
Tangible book value per share of Intellia Therapeutics, Inc. – HAN:38I - TradingView
Intellia Therapeutics, Inc. (NTLA) Stock Forecasts - Yahoo Finance
No-Moat Intellia Therapeutics Provides Pure-Play, Long-Term Exposure to Gene Editing Therapies - Morningstar
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity - Barchart.com
Intellia Therapeutics Bears Growl Again, This Time About Claude AI -- Yawn! (NASDAQ:NTLA) - Seeking Alpha
Intellia Therapeutics Stock Short Interest Rises to 41.97% - Quiver Quantitative
Gene editing stocks fall after Anthropic’s CRISPR-like discovery - Seeking Alpha
Why Is NTLA Stock Jumping 5% Premarket Today? - Stocktwits
Intellia Therapeutics (NTLA) Stock Gets FDA Priority Review For Lonvo Z Gene Editing Therapy - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances - Yahoo Finance
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry? - Yahoo Finance
How (NTLA) Movements Inform Risk Allocation Models - Stock Traders Daily
Cathie Wood’s ARK sells Twist Bioscience stock, buys more Intellia - investing.com
Cathie Wood’s ARK sells Twist Bioscience stock, buys more Intellia By Investing.com - Investing.com Australia
Tracking Cathie Wood: Adding to Gene Editing Leader Intellia, Trimming Brera Holdings - moomoo.com
Cathie Wood’s ARK adds Intellia stock, trims Brera Holdings - Investing.com
Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost? - Yahoo Finance
H.C. Wainwright reiterates Intellia stock rating on FDA review progress By Investing.com - Investing.com Nigeria
Intellia’s Lonvo-z Gains FDA Priority Review for HAE - theglobeandmail.com
Intellia Therapeutics Price Target Maintained With a $25.00/Share by HC Wainwright & Co. - moomoo.com
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug - Yahoo Finance
NTLA Reiterates by Citizens -- Price Target Maintained at $30 - GuruFocus
FDA to Decide on First In Vivo Gene Editor Next Year - GenomeWeb
Intellia Therapeutics Stock Short Interest Rises to 40.35% - Quiver Quantitative
H.C. Wainwright reiterates Intellia stock rating on FDA review progress By Investing.com - Investing.com Canada
NTLA Maintained by Wedbush -- Price Target Raised to $13.00 - GuruFocus
H.C. Wainwright reiterates Intellia stock rating on FDA review progress - Investing.com
H.C. Wainwright reiterates Intellia stock rating on FDA review progress By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Intellia stock rating on FDA review progress By Investing.com - Investing.com India
NTLA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Citizens reiterates Intellia stock rating on FDA priority review By Investing.com - Investing.com Nigeria
Citizens reiterates Intellia stock rating on FDA priority review - Investing.com
Citizens reiterates Intellia stock rating on FDA priority review By Investing.com - Investing.com Australia
Citizens reiterates Intellia stock rating on FDA priority review By Investing.com - Investing.com Canada
2.20%
0.18%
자본화:
|
볼륨(24시간):